For example, neoadjuvant talazoparib has been used in patients with operable BC with a germline BC pathogenic variant [50], cyclin-dependent kinase 4/6 inhibitors are used as a neoadjuvant endocrine therapy for patients with hormone receptor-positive BC [51], and CD73 expression and pathologic stage may influence the effectiveness of neoadjuvant chemotherapy in triple-negative BC [52]. This evidence concerns the gene CDK4 and breast cancer.